Therapy Areas: Respiratory
Anixa partners with OntoChem for initial screening and identification of additional Covid-19 compounds
7 July 2020 -

Biotechnology company Anixa Biosciences Inc (NASDAQ:ANIX) and partner OntoChem announced Monday the completion of the initial in silico screening process and have identified an additional specific compound, as well as multiple analogs, which could function as inhibitors of the main protease (Mpro) under the Covid-19 therapeutics programme.

Based on initial identification of the Mpro scaffold compound, the partnership has established a new in silico library of analog compounds that will be evaluated through additional in silico screening in biological assays. The project reportedly targeted the main Covid-19 virus enzyme, known as the main protease or Mpro, which plays a pivotal role in mediating viral replication.

The partnership has identified four compounds that could disrupt the function of a viral enzyme called an endoribonuclease (NSP-15). The protein Nsp 15 from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV- 2) is 89 % identical to the protein from the earlier outbreak of SARS-CoV. The candidate inhibitors of Mpro are being synthesized and then will be tested in biological assays.

Login
Username:

Password: